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                   Abstract 
 
ESTROGEN AND HYPOXIA REGULATE LEVELS OF VEGF AND ITS  
RECEPTORS IN THE MICE UTERINE CERVIX AND  
ARE EXPRESSED IN HUMAN 
                    Takako Ohashi,  
              B.S. Biology, Appalachian State University 
                         M.S. Biology, Appalachian State University 
               Chairperson: Chishimba Nathan Mowa 
The uterine cervix undergoes significant changes over the course of pregnancy, 
including increase in tissue size, pronounced microvascular remodeling and increase in local 
vascular endothelial growth factor (VEGF) and its receptors. VEGF has been studied in 
various parts of body and in various cancer cells; however the regulation of VEGF in healthy 
uterine cervix has not been examined. We hypothesize the most likely factor to influence 
VEGF in the uterine cervix may include mechanical stress, sex steroid hormones, hypoxia, 
relaxin and cytokines. In the present study we examined: a) the effects of mimicked hypoxia 
(CoCl2) and exogenous estrogen (E2) on the expression pattern of VEGF and its receptors, 
KDR and Flt-1, and b) the expression pattern of and identity of cell types expressing VEGF 
and its receptors in mice (non-pregnant) and human (non-pregnant) uterine cervices.  Our 
present findings: a) show that hypoxia and E2 induce expression of VEGF in the uterine 
cervix of non-diseased, non-pregnant mice; b) show the similarity of VEGF and its receptor 
(Flt-1 and KDR) expression profile in the human uterine cervix to mice uterine cervix; c) 
reveal the cellular pattern of VEGF expression and its receptors (Flt-1 and KDR), in the 
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uterine cervix of rodents. We conclude that VEGF mRNA and protein are altered by hypoxia 
and E2 in a time or dose-dependent manner; are present and variably expressed in the uterine 
cervix of human and that they are synthesized by multiple cell types in both mice and human 
uterine cervix. Collectively, these data shed new insights into the regulation and pattern of 
VEGF expression in the uterine cervix of rodents and human.  
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             Introduction    
The uterine cervix undergoes significant changes over the course of pregnancy, 
including increase in tissue size, pronounced microvascular remodeling and increase in local 
vascular endothelial growth factor (VEGF) and its receptors. These changes are associated 
with increased levels of plasma estrogen (E2) (Downing and Sherwood, 1985). Outside the 
uterine cervix, a range of factors and conditions have been identified to influence the 
expression of VEGF, notably: hypoxia, cytokines [e.g., interleukin-1 (IL-1), tumor necrosis 
factor-α (TNF-α)], growth factors (TGFα2, FGFs, PDGF), advanced glycation end products, 
vasopressor hormones, relaxin, sex steroid hormones, mechanical stress, and many more 
(Unemori et al., 1999; Koos et al., 2005; Taki et al., 2012; Donnelly et al., 2013). 
VEGF belongs to a family of closely related growth factors, including VEGF-A, -B, -
C, -D, -E and placenta growth factor (PGF) (Yan et al., 2011). VEGF-A or simply VEGF, 
has several biological effects and exists as several splice variants (Yan et al., 2011). These 
biological effects are largely mediated by two receptors (VEGFRs): kinase domain region 
(KDR) and fms-like tyrosine kinase-1 (Flt-1) (De Vries et al., 1992; Ferrara and Davis-
Smyth, 1997). In female reproductive biology, VEGF is essential for a variety of ovarian and 
uterine endometrial functions that are also associated with E2, such as corpus luteum 
angiogenesis, mediation of cyclical growth of blood vessels and maturation of endometrium 
(Shibuya, 1998; Challis, 2000; Breeveld-Dwarkasing et al., 2003). VEGF has been studied in 
various ovarian diseases (i.e., endometriosis)(Wang et al, 2011), and in various cancer cells 
2 
 
(Roskoski, 2007). However, the functions of VEGF in the uterine cervix are still not fully 
explored, and the role of sex steroids and hypoxia in regulating the expression of VEGF and 
its receptors in the non-diseased uterine cervix has not been examined. 
We have previously demonstrated the existence and expression profile of VEGF 
(164) and VEGFRs, in the uterine cervix of rodents (mice and rats); deciphered genes 
regulated by VEGF in the uterine cervix using DNA microarray analysis (Ferrara et al., 1998; 
Mowa et al., 2004); and more recently examined VEGF’s specific physiological roles in 
cervical remodeling (CR), such as cervical epithelial cellular growth, immune cell 
recruitment and migration to the lumen of the uterine cervix and induction of an 
inflammatory response (Dussably et al., 2003; Mowa et al., 2008a; Nguyen et al., 2012).  
Of these previously cited factors, the most likely to influence VEGF in the uterine 
cervix may include mechanical stress, sex steroid hormones, hypoxia, relaxin and cytokines, 
based on the following rationale: a) the growing fetus exerts increasing gravitational pressure 
(mechanical stress) on the uterine cervix (Zhang et al., 2009); b) there are temporal and 
spatial relationships between E2, relaxin, VEGF and VEGFRs during pregnancy; E2 and 
relaxin are known to induce robust VEGF expression in the uterus and elsewhere (Unemori 
et al., 1999); c) both  pregnancy and  infection induced by lipopolysaccharide (LPS) 
introduce cytokines in the uterine cervix, and LPS promotes mRNA expression of VEGF and 
its receptors (Dussably et al., 2003); d) if the robust growth of the uterine cervix, particularly 
in the last half of pregnancy, outgrows the micro-vascular network, as may be the case in 
cancer, it will lead to hypoxia, which is the most potent inducer of VEGF expression outside 
of the uterine cervix (Unemori et al., 1999; Taki et al., 2012). 
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In the present study, we examine: a) the effects of hypoxia and exogenous E2 on the 
expression pattern of VEGF and VEGFRs in non-pregnant, non-diseased mouse uterine 
cervix; b) details of the expression pattern and identity of cell types expressing VEGF and its 
receptors in mice (non-pregnant) and human (non-pregnant) uterine cervix.     
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            Materials and Methods 
Subjects used in the study  
a). Mice: Non-pregnant and timed pregnant (days 11 and 17, untreated) female 
C57BL6/129SvEv mice, purchased from Charles Rivers, were used in the present studies. All 
experimental procedures were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals of the local institution (Appalachian State University) and the NIH 
guidelines (NIH publication number 86-23). All efforts were made to minimize the number 
of animals used and discomfort or suffering of the animals. 
b). Humans: Human uterine cervical tissues from four non-pregnant women (Sheffield, 
England), were also used in the present study. These tissues were harvested, fixed and 
processed in paraffin blocks using established standard procedures by our collaborator, Dr. 
Dilly Anumba (Sheffield University Medical School, Sheffield, England). The tissue samples 
were obtained using 8 x 5 x 5 mm cervical punch biopsies during abdominal hysterectomy 
(Table 1). 
Animals, surgery, treatments and tissue harvest 
Non-pregnant mice: 
a). Surgeries (Ovariectomy): Non-pregnant mice were ovariectomized (ovary removal), 
in order to prevent confounding effects of indigenous ovarian sex steroid hormones. Prior to 
surgery, animals were anaesthetized using a mixture of ketamine (43-129 mg/g body weight) 
and xylazine (8.6-26 mg/g body weight).  To prevent post-surgery infections animals were 
administered with Baytril® antibiotic (Bayer, Leverkusen, Germany), immediately after the
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 surgery. Animals were then rested for seven days post-surgery, to allow complete excretion 
residual ovarian sex steroid hormones, confirmed during tissue extraction by significant 
uterine size reduction. At this time, animals with normal uterine size were eliminated from 
the study. 
b). Treatments: Non-pregnant ovariectomized mice were then treated with either 
mimicked hypoxia (cobalt chloride, CoCl2) or exogenous sex steroid hormones (17β- 
estradiol, E2), to examine the impact on the VEGF and VEGFRs (KDR and Flt-1) 
expressions in the uterine cervix, as described below: 
i). Effect of CoCl2 (mimicked hypoxia) on expression of VEGF and receptors: Mice 
were treated with CoCl2 (38.95 mg/kg body weight, dissolved in 0.9% sodium chloride, 
NaCl) in a time-dependent manner (30, 90 and 180 min), in order to simulate hypoxia, as 
described previously (Mastumoto et al., 2010). CoCl2 solution was administered intra-
peritoneally (IP) and intra-vaginally (intra-luminally) (IV) (n=7).   
ii). E2 administration: Mice were treated with either vehicle only (sesame oil) 
(negative control group) or exogenous E2 dissolved in sesame oil, in dose dependent manner 
(8 mg, 4 mg and 2 mg/kg body weight, respectively, n=7), administered via IP once daily for 
4 days (Mowa et al., 2008b). 
     c). Tissue harvest: Following the treatments, mice were administered with a lethal 
injection of sodium pentobarbital (Sleepaway®, Fort Dodge Laboratories Inc., Burlingame, 
CA) and perfused intra-cardially with 0.9% NaCl to flash out blood cells from the tissues. 
Uterine cervical tissues were then carefully dissected out under a stereomicroscope. Tissues 
were weighed immediately and tissues designated for Western blot analysis and real time 
polymerase chain reaction (real time PCR) were immediately stored at -80ºC until 
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processing. Tissues designated for morphological studies were fixed in 4% paraformaldehyde 
for minimum 24 h, followed by 0.1 M PBS for minimum 24 h at 4°C, then dehydrated with a 
(70%, 95% twice, 100%) for a minimum of 2 h per dilution followed by two changes of 
xylene 2 h each, and embedded in paraffin and stored in room temperature (RT) until 
sectioning.  
Pregnant mice:  
  Untreated mice in early and late pregnancy (days 11 and 17 of gestation, respectively; 
n=4) were used to examine the cellular pattern of VEGF and VEGFRs expressions. 
  Mice were sacrificed as described previously; tissues were weighed immediately and 
stored appropriately.    
 Techniques Used in the Study: 
a). Basic Morphological Studies [hematoxylin (nucleus stain) and Eosin (cytoplasmic 
stain) staining]: Experiments were undertaken to examine the basic histology of uterine 
tissues from mice (non-pregnant and pregnant) and human uterine cervix, as described here. 
Paraffin fixed sections were cut into 5 µm-thick sections using a microtome (Leica RM 2125 
RTS, Leica microsystems, USA) and incubated at 37ºC overnight. Paraffin sections were de-
paraffinized using two changes of xylene, rehydrated using serially diluted alcohol solutions 
(100% twice, 85%, 70% and 50%), followed by distilled water and 0.1 M PBS, for 10 min 
each. Tissues were stained with standard H & E staining procedure (VWR international LLC, 
USA) and imaged using Olympus DSU IX81 (Olympus, USA). 
b). Protein Expression Studies: Cellular localization and tissue quantification of VEGF 
and VEGFRs protein expressions were studied using confocal immunofluorescence and 
Western blot analysis, respectively, as described below. Hypoxia inducible factor-α (HIF-α), 
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which is stabilized following CoCl2 treatment, was used as a positive control protein for 
hypoxia studies:  
i). Western Blot Analysis: Quantitative analysis of protein expression was performed 
to supplement confocal immunofluorescence data. Total protein was isolated from previously 
harvested frozen tissues using standard protein isolation protocol. The concentrations of the 
protein samples were determined by Spectrophotometer (Thermo Scientific, USA) at 595 nm 
(absorbance). Proteins were separated by gel electrophoresis (10 µg/well) at 125 V for 90 
min then transferred to PVDF membrane, incubated in blotto (5.0 g non-fat dry milk and 100 
ml of 1 X TBST) at 4°C for 24 h. Membranes were stained with specific primary antibodies 
(VEGF, Flt-1, Flk-1/KDR, HIF-α) at 1:500 dilution as described by manufacturer and 
incubated overnight at RT. Membranes were then washed with 1XTBST (5 min each x 3), 
and incubated with secondary antibody (i.e., Donkey anti-rabbit IgG HRP conjugated, 
Streptactin HRP) for 1 h at RT, followed by 1 X TBST washes (5 min each x 3), fourth wash 
with 1 X TBS. Membranes were then covered with limunol-enchancer/peroxidase solution 
(VWR, USA) and developed. Images were analyzed with ImageJ program (NIH). The 
specific bands of interest were identified using a standard ladder with known molecular 
weight (β-actin). 
ii). Confocal Immunofluorescence: Experiments were designed to visually identify 
the specific cell types expressing the proteins of interest, and to complement Western Blot 
analysis. Paraffin fixed sections were prepared as described previously and incubated with 
primary antibodies, as described by the manufacturer (Santa Cruz Biotechnology, Santa 
Cruz, CA). Briefly, after de-paraffinization, non-specific protein bindings were blocked using 
10% normal goat serum (NGS, in 0.1 M PBS) (Vector laboratories Inc., USA) at RT for 30 
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and 45 min for mouse and human tissues, respectively. Tissues were then incubated with 
appropriate primary antibodies at 0.5 µg/ml (VEGF 164, Flt-1 and Flk-1/KDR) overnight in 
humid chambers at 4ºC, followed by washes (5 min each x 3) in 0.1M PBS. Control sections 
were incubated with 10% NGS only. All sections were incubated with fluorescence-tagged 
secondary antibodies at 0.5 µg/ml for 1 h, followed by washes (5 min each x 3) in 0.1 M 
PBS. Nucleic acid was counterstained with 5 µM Sytox®Green for 5 min, followed by 
additional 5 min washes in 0.1 M PBS.  Images were obtained using a confocal microscope 
(Zeiss LSM510, Thornwood, NY). 
c). Gene Expression Studies: Gene expression analysis was performed using real time 
PCR to examine the effects of E2 and mimicked hypoxia on the mRNA expression of VEGF, 
VEGFRs and HIF- in the uterine cervix of non-pregnant mice. Gene expression analysis 
was performed in three steps, as described below.  
i). Tissue processing, messenger RNA isolation and quantification: Total RNA was 
isolated from individual uterine cervices using the RNeasy Mini Kit (Qiagen, Valencia, CA) 
and purity of each sample was determined using Nanodrop Spectrophotometer (ND-2000, 
Thermo Scientific, USA). Total RNA was diluted (1.0 µg/9.5 µl) in RNase-free deionized 
(DI) water, stored at -80°C until processed for reverse transcriptase PCR (RT-PCR).  
ii). Reverse transcriptase PCR (RT-PCR): Total RNA from the uterine cervical tissues 
was reverse-transcribed and amplified in an Eppendorf Thermocycler (Hamburg, Germany) 
using reagents and protocol from the manufacturer (Applied Biosystems, Foster, CA). 
Briefly, to generate complementary DNA (cDNA),  diluted total RNA were incubated in a 
water bath for 5 min at 65°C, followed by incubation at RT for 10 min. 9.5 μl of reverse 
transcriptase master mix was added to each tube, which comprised of: reverse transcriptase 
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buffer and Magnesium chloride (Mg Cl2)[2 μl each per RNA (1.0 µg/9.5 µl)], dNTP and 
RNAse-free water [2 μl each per RNA (1.0 µg/9.5 µl)], RNase inhibitor [0.5 μl per RNA (1.0 
µg/9.5 µl)]  , and random hexamers [1 μl per RNA (1.0 µg/9.5 µl)]. Lastly, 1.0 μl of MuLV 
reverse transcriptase was added to each tube. All materials were purchased from Applied 
Biosystems (Foster, CA). One tube without reverse transcriptase enzyme served as a non-
template control (NTC) for DNA contamination. The Thermocycler was programmed at 
25°C for 10 min, 42°C for 2 h, 95°C for 5 min, and 4°C. The generated total cDNA was then 
used to evaluate mRNA levels of the genes of interest, as described below.  
iii). Real-time PCR: Relative expressions of VEGF, KDR and Flt-1 were evaluated 
using real time PCR. Genes of interest (DNA) were amplified using the Applied Biosystems 
real time-PCR machine (ABI 7300 HT) with the GeneAmp 7300 HT sequence detection 
system software (Perkin-Elmer Corp), assays and protocol provided by the manufacturer 
(Applied Biosystems, Foster, CA). Briefly, TaqMan® Gene Expression Assays, which are 
pre-designed and pre-optimized gene-specific probe sets, were utilized and PCR reactions 
were set up in 96-well plates (25 µl per well). The reaction components comprised of 1.0 
µg/5.0 µl of previously synthesized cDNA, 12.5 µl of 2 X Taqman® Universal PCR Master 
Mix, 1.25 µl of 20 X Assays-on-Demand TM Gene Mix (e.g., VEGF), and 6.25 µl of  real 
time PCR-grade RNAse-free water. The program was set as follows: 50°C for 2 min and 
95°C for 10 min and then 40 cycles of 95°C for 15 s and 60°C for 60 s. The relative 
expression of the genes of interest were calculated from the threshold cycles with the 
instrument’s software (SDS 2.0) (Applied Biosystems, USA) and normalized against Gusβ. 
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Statistical Analysis  
Data were analyzed using t test and ANOVA for multiple comparisons. p-values 
equal to, or less than 0.05 were considered to be statistically significant.
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                    Results 
Hypoxia simulation induces morphological changes and regulates mRNA and protein 
expression of VEGF and its receptors in the uterine cervix of mice 
a). Basic histological changes: H & E staining performed to explore the basic 
histological changes in the uterine cervix of mice after mimicking hypoxia using CoCl2 
revealed an increase in nuclei staining at 3 h post CoCl2 treatment, signifying an increase in 
cellular nuclei density, likely from endothelial cells due to an apparent increase in 
angiogenesis, compared to negative control (Figure 1A-B).  
b). Hypoxia simulation induces changes in expression of HIF-α, VEGF and VEGFRs 
mRNA and protein in uterine cervix of non-pregnant mice:  
i). Western blot: Levels of HIF-1α, which was used as a positive control protein to 
determine whether hypoxia was successfully simulated, showed up-regulation in a time-
dependent manner following the treatment of the animals with CoCl2, significantly higher 
than the control at 3 h post injection (Figure 2A), indicating the effectiveness of CoCl2 in 
simulating hypoxia. The expression of VEGF protein showed significant up-regulation at 30 
min post CoCl2 injection, but, thereafter, declined in a temporal fashion, to our surprise 
(Figure 2B, p ≤ 0.05). Overall, the protein expression of VEGF receptors were regulated 
variably; specifically, the up regulation of Flt-1 was most noticeable at 1.5 h post CoCl2 
administration with no statistical significance, whereas, expression of KDR protein was 
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significantly up-regulated at 30 min post CoCl2 administration, followed by a decline to 
control level (p ≤ 0.05) (Figure 2C-D).  
ii). Confocal Immunofluorescence: Data generated from confocal 
immunofluorescence were used to supplement data obtained by Western blot analysis. The 
intensity of VEGF protein expression was found to be more pronounced at 3 h post CoCl2 
administration compared to the negative control group (Figure 3A-B). Similarly, the intensity 
of Flt-1 expression was much greater at 3 h post CoCl2 administration compared to the 
negative control group (Figure 3C-D). No significant differences were observed between the 
negative control group and 3 h post CoCl2 administration for KDR expression, consistent 
with the data generated from Western blot (Figure 3E-F).  
iii). Real time PCR: Messenger RNA expression of the positive control gene, HIF-1α, 
surprisingly down-regulated immediately after administration of CoCl2 (Figure 4A, p ≤ 0.05).  
The expression of the VEGF gene showed regulation in time dependent manner with levels 
above control by 3 h post CoCl2 administration (Figure 4B, p ≤ 0.05). Flt-1 gene expression 
was found to be significantly higher than control level at 3 h post CoCl2 administration 
(Figure 4C, p ≤ 0.05). On the other hand, the gene expression of KDR was down-regulated 
time-dependently (Figure 4D, p ≤ 0.05).  
 
E2 regulates histomorphology of uterine cervix and expression of VEGF and its receptors 
in non-pregnant mice 
a). E2 induces changes in the histomorphology of uterine cervix: Uterine cervices from 
non-pregnant ovariectomized mice treated with E2 showed significant changes in tissue 
weight compared to the control group (Figure 5A-B) however, there were no significant 
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differences between the treatments (2 mg/kg-8 mg/kg). Hypertrophy of uterine cervical 
epithelial cells and increased mucous secreting cells were observed (Figure 6A-B).  
b). E2 regulates expression of VEGF and VEGFRs proteins:  
i). Western blot: Data generated from Western blot shows that E2 up regulated VEGF 
(p ≤ 0.05) and Flt-1proteins in a dose-dependent manner (Figure 7A-B), however the level of 
VEGF proteins were found to be above the control level only at high dosage (p ≤ 0.05) . The 
expression of KDR, on the contrary, was found to be down regulated below control level (p ≤ 
0.05) (Figure 7C). 
VEGF and VEGFRs (Flt-1 and KDR) exhibit increased protein expressions in late (day 
17) compared to early (day 11) pregnancy. However, surprisingly protein levels of VEGF 
and Flt-1throughout pregnancy were found to be lower than the control group, i.e., uterine 
cervix of ovariectomized non-pregnant (data not shown). 
ii). Confocal Immunofluorescence: were used to complement data generated from 
Western blot analysis. VEGF expressions in the negative control group were largely 
localized in the epithelial and just below it, i.e., sub-epithelial compartments (Figure 8A). 
Cellular localization of VEGF in E2-treated (high, 8 mg/kg) animal was more widespread, 
beyond the epithelial and sub-epithelial compartments, and included stromal cells (Figure 
8B). Flt-1 expression was visually noted in both the negative control group and in E2-treated 
mice. Intensity of Flt-1 expression was more pronounced in E2-treated mice, particularly near 
and on the epithelia (Figure 8C-D). Minimal differences in KDR expression were observed 
between the negative control group and E2-treated mice (Figure 8E-F). 
iii). Real time PCR: Although differences in VEGF gene expressions between 
negative control and E2-treated groups shows no statistical significance, according to the real 
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time PCR analysis, there was a consistent dose-dependent increase in the expression of this 
gene. On the contrary, Flt-1 mRNA was below control level and down regulated in dose 
dependent manner. Level of KDR mRNA was also below control level, and showed no 
expression pattern (Figure 9A-C). 
 
VEGF and its receptors are expressed in the uterine cervix of non-pregnant women  
Data generated from confocal immunofluorescence of human uterine cervix shows 
presence of VEGF and its receptors (Figure 10A-C). All the three proteins of interest were 
found to be expressed intensely. However, due to different self-reported phases of the 
menstrual cycle, there were variations in both the intensity of expression and cellular 
localization between the subjects. For instance, expression of VEGF was most intense in 
subject NPO8 and was largely localized in apparent stromal cells (Figure 10A), whereas, 
expression of Flt-1 and KDR were both expressed in all the women, but their cellular 
localization was largely confined to epithelial cells (Figure 10B-C). These patterns of cellular 
localization of VEGF and its receptors in human uterine cervix were comparable to the 
uterine cervix of ovariectomized non-pregnant mice (Figure 10D-F).
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               Discussion 
 The human female reproductive tissues undergo marked changes during gestation and 
menstrual phases. Supporting and sustaining these tissue changes require an equally dynamic 
vascular network remodeling that ensures access to essential resources and removal of toxins 
and metabolic waste products from cells (Andersson et al., 2008). VEGF is the best 
characterized angiogenic regulator and is the key architect of the vascular network. Our prior 
studies have characterized the presence and the expression profile of VEGF (164) and its 
receptors in the uterine cervix of pregnant rodents over the course of pregnancy (Shifren et 
al., 1996; Mowa et al., 2004; Simon and Einspanier, 2009; Sharma et al., 2011). We do know 
in other tissues that hypoxia (HIF-1α) caused by cell growth (i.e., tumor cells) and reduction 
of cellular O2 supplies (i.e., low blood pressure) is the most potent inducer of VEGF (Calbet, 
2003, Yao et al., 2010) and that sex steroid hormones, such as E2, in the uterus, induces 
VEGF expression (Mowa et al., 2004). Further, recent studies in the uterus have revealed 
complex molecular and signaling interplay between E2 and hypoxia in the induction of 
VEGF expression (Koos et al., 2005). However, the factors that induce expression of 
endogenous VEGF and its receptors in the non-diseased uterine cervix are not completely 
known. Here, we’ve show that: i) hypoxia and E2 induce expression of VEGF in the uterine 
cervix of non-pregnant, non-diseased mice; ii) the uterine cervix of human expresses VEGF 
and its receptors (Flt-1 and KDR), similar to mice; iii) reveal the cellular pattern of VEGF 
expression and its receptors (Flt-1 and KDR), in the uterine cervix of rodents. Collectively, 
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these data shed new insights into the regulation and pattern of VEGF expression in the 
uterine cervix of rodents and human.  
 We demonstrate in the present study that chemical simulation or mimicking of 
hypoxia using CoCl2 alters expression of VEGF and its receptors in the uterine cervix, in a 
time-dependent manner. Local tissue oxygen tension is tightly regulated, as it plays a critical 
role in tissue survival and function, under normal physiological conditions. Tissue oxygen 
levels below normal (normoxia, i.e., O2 ˃ 3%) lead to hypoxia and, consequently, an increase 
in the concentration of a hypoxia-associated transcription factor, such as HIF-1α and HIF-2α, 
which are degraded rapidly in normoxic (O2 ˃  3%) conditions by von Hippel-Lindau protein 
(pVHL) mediated ubiquitination. HIF-1α regulates expression of more than 100 genes, and 
through signaling cascades it regulates those that are not associated with hypoxia, such as 
estrogen. CoCl2 interfere the interaction of HIF and pVHL either by disabling the activity of 
the critical enzyme, HIF hydroxylase (prolyl hydroxylase domain-containing enzymes, 
PHDs) by binding on its iron binding site, and/or by binding on HIF-α oxygen-dependent 
degradation domain (ODD) inhibiting the binding of pVHL to HIF-α, even when HIF-α is 
hydroxylated (Ho and Bunn, 1996; Epstein et al., 2001; Young et al., 2003; Yuan et al, 
2003). The effectiveness of CoCl2 in the present study is shown by a time-dependent 
accumulation of HIF-1α protein; increase in expression of VEGF and proliferation of cells in 
the tissue, likely to be vascular endothelial cells. However, we are not completely sure of the 
specific cell type, further study with immunostain with specific endothelial cell markers (i.e., 
vWF) is necessary to identify these cells. Because the uterine cervix undergoes marked 
growth over the course of pregnancy, especially in the last two thirds of pregnancy, such 
pronounced growth is likely to induce hypoxia and, consequently, accumulation of HIF-1α 
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and expression of VEGF. We do know that hypoxia is generally induced during significant 
tissue growth or under the influence of growth promoters, such as estrogen and relaxin. For 
instance, in tumors, when the tissue reaches approximately 0.2-2.0 mm in diameter, without 
an equivalent change in blood supply, hypoxia is induced, which will then turn on the 
angiogenic “switch” via induction of HIF-1α (Koh and Powis, 2012). Indeed, our previous 
studies had shown a close temporal relationship between expression of VEGF/receptors and 
gestational age (Mowa et al., 2004). Moreover, it is interesting to note that women in Peru, 
when close to their due date, can intentionally induce the birth process by going to higher 
altitudes, where oxygen levels are low or conditions are relatively hypoxic (Bonney, 2012). 
However, more studies are needed to characterize the role of HIF-1α in pregnancy and 
decipher the molecular mechanisms and pathways that mediate these biological effects in the 
uterine cervix under physiological and aberrant conditions, such as preterm labor.  
 Sex steroid hormones, including E2, are known to differentially alter the expression of 
VEGF and its receptors in a variety of tissues (Cullinan-Bove and Koos, 1993; Hyder et al., 
1996; Hyder et al., 1997; Yoshigi and Keller, 1997; Hyder et al., 1998; Ruohola et al., 1999; 
Classen-Linke et al., 2000; Hyder al., 2000; Mueller et al., 2000; Nakamura et al., 2000; 
Stoner et al., 2000; Bogin and Degani, 2002; Buteau-Lozano et al., 2002; Stoner et al., 2004). 
While E2 promotes expression of VEGF in the uterus and mammary tumors in the female rats 
(Nakamura et al., 2000), regulation of VEGF by E2 in some tissues is much more complex 
and appears to be context-dependent. For instance, whereas, E2 induces VEGF gene 
expression in Ishikawa and MCF-7 breast cancer cells (Ruohola et al., 1999; Mueller et al., 
2000; Buteau-Lozano et al., 2002), it (E2) decreases VEGF gene expression in HEC1A 
endometrial cancer cell lines, even though they are also estrogen receptor (ER)-positive 
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(Stoner et al., 2000). Although ER and VEGF and its receptors have been described 
previously in the uterine cervix and appear to have a temporal relationship, until now, very 
little was known whether there was a cause-and-effect relationship between the two factors. 
Here, we have shown that exogenous E2 induces expression of VEGF mRNA and protein in 
the uterine cervix in a dose-dependent manner. Our present findings correlate with studies 
that used rodent uterus, Ishikawa and MCF-7 breast cancer cells, as cited above (Ruohola et 
al., 1999; Mueller et al., 2000; Buteau-Lozano et al., 2002).  
 For now, it is not clear exactly how E2 induces expression of VEGF and its receptors 
in the uterine cervix and how this relates to uterine cervical events, notably CR. It is, 
however, intriguing to note some striking similarities and overlap between the biological 
effects of VEGF with another E2 responsive gene whose actions on the uterine cervix have 
been extensively characterized, namely relaxin. Both relaxin and VEGF: a) are responsive to 
E2; b) induce proliferation of uterine cervical epithelial cells and expression of endothelial 
nitric oxide synthase (eNOS) in the uterus, dose-dependently (Bani-Sacchi et al., 1995; 
Unemori et al., 1999; Dschietzig and Stangl, 2003); c) reduce tissue tensile strength in 
rodents and; d) exert similar vascular effects (normal and aberrant), such as vasodilation 
(Bani and Bigazzi, 1984; St-Louis and Massicotte, 1985). For instance, in women with 
scleroderma administered continuous subcutaneous infusion of relaxin over 24 weeks, 
relaxin mimics typical VEGF-like vascular physiological effects, described in human 
pregnancy, particularly increased blood volume, flow and angiogenesis (Seibold, 2002). 
Notable side effects reported included hyper-menorrhagia (excess bleeding), which is likely 
due to abnormal vascular permeability or vessel leakage, another signature characteristic of 
aberrant VEGF concentration (Seibold, 2002). Lastly, a recent report concluded that the 
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primary role of relaxin mainly involves regulation of body fluids and circulation hemostasis, 
roles that are comparable to VEGF action (Dschietzig and Stagl, 2003).  
The effects of VEGF are known to be mediated by its two receptors, Flt-1 and KDR, 
which have been localized previously in the uterine cervix by our group. Here, we show that 
the mRNA and protein levels of both receptors are variably regulated by simulating hypoxia 
and exogenous E2. It is not clear which receptor is likely to mediate the biological effects of 
VEGF that have been so far reported, e.g., epithelial proliferation, immune cell recruitment, 
tensile strength alteration and others.  However, we do know that in other tissue types 
VEGFR2/KDR/Flk-1 is the main regulator of VEGF under normal physiological conditions; 
it has been shown to mediate several biological processes such as proliferation, increase in 
vascular permeability, cell migration and inhibition of cell apoptosis. On the other hand, 
VEGFR1/Flt-1 is known to have no direct cellular effect, but leads to increased expression of 
proteases (i.e., plasminogen activator/ inhibitor-I) resulting in degradation of extracellular 
matrix structure, monocyte migration and sequestration of excess VEGF by the soluble form 
of Flt-1 (Roskoski, 2007). Lastly, our present study shows presence of VEGF and its 
receptors in the stromal and epithelial cells of the uterine cervix in human, i.e., non-pregnant 
women with self-reporting phases of menstrual cycles. The similarities in the cellular 
expression of these molecules between rodents and human could potentially imply existence 
of comparable mechanisms and biological actions in these two species, and, possibly, 
suitability of rodents as models for studying VEGF’s role in CR. 
 We conclude that levels of VEGF are altered by hypoxia simulation and exogenous 
E2 in a time- or dose dependent manner in the mice; are present and variably expressed in the 
uterine cervix of non-pregnant women and that they are synthesized by multiple cell types of 
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both mice and human uterine cervix. These findings may shed new insights into deciphering 
the role of VEGF and its underlying mechanism in CR, as it relates to pre-term labor, an 
obstetrical problem affecting both mothers and babies.     
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     Tables  
Table 1: Backgrounds of human subjects from which uterine cervical tissues were obtained: Uterine cervical 
tissues were harvested from four women, with self-reporting phases of menstrual cycle, immediately after total 
abdominal hysterectomy. Harvested tissues were then processed and imbedded in paraffin blocks and sections 
were cut and analyzed for histology and confocal immunofluorescence (source of tissues; generously provided 
by Dr. Dilly Anumba). 
 
SUBJECTS REFERENCE NUMBER  NP05 NP06 NP07 NP08 
 
 
 
 
B 
A 
C 
K 
G 
R 
O 
U 
N 
D 
Age (years) 35 40 44 41 
Smoking status No No No Yes 
Last Cervical Smear in 5 years Yes Yes Yes Yes 
Last smear normal Yes Yes Yes Yes 
Menopausal Symptoms No No No No 
Hysterectomy type Total Total Total Total 
Surgery indication  
a. Menorrhagia Yes Yes Yes Yes 
b Malignant No No No No 
c Chronic Pelvic Pain Yes Yes No Yes 
d Other benign No No No No 
Menstrual Phase 
(secretory/menstrual) 
S M S M 
Hormonal treatment, last 6 weeks No No No No 
Number, previous pregnancies 3 2 1 1 
Number, miscarriages 1 0 0 0 
Delivery type (Vaginal/caesarian) C V C V 
Vaginal infection, last 6 weeks No No NA No 
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Figure 1
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effects of CoCl2 on histomorphology of mice uterine cervix: H&E staining were performed on uterine 
cervix of mice treated with CoCl2. A) Negative control group (Left column, 0.9% NaCl only); B) CoCl2-treated 
group (Right column, 3 h treatment, 38.95 mg/kg body weight) (20x) “B” compared to “A” shows increased 
density in cellular nuclei (dark blue dots, *), indicative of cell proliferation, most likely endothelial cells, which 
occurs during angiogenesis. e= epithelia; *= stromal cells. 
A B 
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e 
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* 
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* 
Control CoCl
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effects of CoCl2 on expression of VEGF, KDR and Flt-1 proteins in the uterine cervix of non-
pregnant mice, as revealed by Western Blot analysis: Mice were either treated with CoCl2 (38.95 mg/kg body 
weight) for 30 min, 1.5 h and 3 h, respectively. Levels of HIF-1α showed up-regulation in a time-dependent 
manner however it was only significantly higher than the control at 3 h post injection (A). The expression of 
VEGF protein showed significant up-regulation at 30 min post CoCl2 injection, but, thereafter, declined, in a 
temporal fashion (B).  The up regulation of Flt-1 was most noticeable at 1.5 h post CoCl2 administration with no 
statistical significance (C), whereas, expression of KDR protein was significantly up-regulated at 30 min post 
CoCl2 administration, followed by a decline to control level (D). 
 * = p < 0.05; n=3. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Effects of CoCl2 on expression of VEGF, Flt-1 and KDR proteins in the mice cervix, as revealed by 
confocal immunofluorescence: Uterine cervices of mice treated with CoCl2 were immunostained with different 
primary antibodies of target proteins (red fluorescence) and counterstained with Sytox®green, which is 
displayed as green fluorescence in the cellular nuclei. Images on the left column (A, C, E, x40) were from 0.9% 
NaCl only-treated animals (negative control group) and those on the right column were from CoCl2-treated 
animals (B,D, F, x40) (3 h, 38.95 mg/kg body weight): CoCl2 treatment induced a more pronounced expression 
of the target proteins (VEGF: A vs. B; Flt-1: C vs. D) compared to control, except for KDR (E vs. F) in both 
stromal and epithelial cells;. e = epithelia; red/yellow = cells with positive protein expressions; green = cellular 
nucleic. 
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Figure 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effects of CoCl2 on mRNA expression of HIFα, VEGF, KDR and Flt-1 in the uterine cervix of non-
pregnant mice, as revealed by real-time PCR: Treatment of mice with CoCl2 (38.95 mg/kg) for 30 min, 1.5 h 
and 3 h, down-regulated mRNA expression of HIF- immediately after administration of CoCl2 (A), VEGF (B) 
and Flt-1 (C) in the cells of the uterine cervix, in a time-dependent fashion with levels above control by 3 h post 
CoCl2 administration.  The gene expression of KDR was down-regulated time-dependently except that of KDR 
(D). * = p < 0.05; n=3. 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Effects of pregnancy and 17β-estradiol on wet weight of mice uterine cervical tissue: The wet weight 
(g) of uterine cervix increased between early and late pregnancy (days 11 and 17 of gestation, respectively) (A) 
and E2-treated (2 mg, 4 mg, and 8 mg/kg body weight) (B) mice compared to their respective controls however, 
there were no significant differences between the different E2 treatment dosages. NP=non-pregnant; C=negative 
control. * = p < 0.05; n=3.  
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Effects of 17β-estradiol on the histomorphology of mice uterine cervix Treatment of mice with E2  
induced uterine cervical tissue edema, demonstrated here as “dispersed” or less dense cell nuclei, and also 
increase in goblet cells were observed (B)(8 mg/kg body weight) compared to negative control group (A)(0.9% 
sesame oil only). e = epithelia; s = stromal cells.  
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Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effects of 17β-estradiol on expression of VEGF, KDR and Flt-1 proteins in the uterine cervix of non-
pregnant mice, as revealed by Western Blot: E2 altered protein expression of VEGF however the level of VEGF 
proteins were found to be above the control level only at high dosage (A)(8 mg/kg body weight) while Flt-
1showed up-regulation in dose-dependent manner (B)(2 mg, 4 mg and 8 mg/kg body weight) whereas KDR was 
down regulated below the control level (C). * = p ˂ 0.05; n=3.  
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Effects of 17β-estradiol on expression of VEGF, Flt-1 and KDR proteins in the mice uterine cervix, as 
revealed by confocal immunofluorescence: Uterine cervices of mice treated with E2 were immunostained with 
different primary antibodies of target proteins (red fluorescence) and counterstained with Sytox®green, which 
is displayed as green fluorescence in the cellular nuclei. E2 was found to alter protein expression of VEGF (A) 
and its receptors (Flt-1, B; KDR, C, respectively) (8 mg/kg body weight) in uterine cervical tissue of mice.  
Both expression of VEGF and Flt-1 were up-regulated, whereas, KDR was down-regulated. Images on the right 
column (B, D, F) are from animals treated with E2 and those on the left column (A, C, E) are from the negative 
control group (sesame oil only). e = epithelia; red/yellow = cells with positive protein expressions; green = 
cellular nucleic. 
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Effects of 17β-estradiol on mRNA expression of VEGF, KDR and Flt-1 in the uterine cervix of non-
pregnant mice, as revealed by real time PCR: E2 treatment altered mRNA expression of the target genes 
differentially (E2: 2 mg, 4 mg/kg and 8 mg/kg body weight): A) It up regulated VEGF mRNA expression dose-
dependently (A);  down regulated Flt-1 mRNA expression (B); and had a varied influence with no expression 
pattern on KDR mRNA expression (C). * = p ˂ 0.05; n=3. 
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Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: VEGF and VEGFRs protein expressions in the uterine cervix of human and mice: Confocal 
immunofluorescence of VEGF and its receptors (Flt-1 and KDR) were localized in the uterine cervical cells of 
non-pregnant human (Top row, Figure 10A-C) and mice (Bottom row, Figures 10D-F). Red/yellow = cells with 
positive protein expressions; green = cellular nucleic staining
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